Dedicated
RESOURCES AND INFORMATION
Please select the most relevant therapeutic area below for dedicated resources and information relating to the efficacy, safety and usage of XELJANZ.
References
  1.  XELJANZ (tofacitinib citrate) Summary of Product Characteristics
PP-XEL-GBR-3107. Aug 2021
XELJANZ Risk Minimisation Programme (RMP) materials, including a Patient Alert Card, Prescriber Checklists and a Prescriber Brochure are available from https://www.medicines.org.uk/emc/. Patients treated with XELJANZ should be given the Patient Alert Card.

© 2021 Pfizer Pte Ltd. All rights reserved.


The information provided in this site is intended only for Health Care Professionals in Singapore. The products discussed herein may have different product labelling in different countries. Pfizer Corporation Singapore Limited is a subsidiary of Pfizer Inc, a pharmaceutical company committed to helping people improve their health by discovering and developing medicines.